MigVax was established Established in 2020 via a leading investment from OurCrowd, the crowdfunding venture investment platform, MigVax set out to modify a well-established coronavirus vaccine developed by Migal for the immunization of poultry, and to use its advanced methodologies to create its innovative oral subunit vaccine for the immunization of humans, starting with the COVID-19. The COVID-19 vaccine project initiated upon a inter-disciplinary research team successful development of a vaccine against Infectious Bronchitis Virus (IBV), an avian (poultry) Coronavirus with high similarity to today’s human COVID-19 that uses the same infection mechanism. Given the similarity, and following required genetic adjustments, the same vaccination concepts should apply. The inter-disciplinary research group is uniquely qualified to carry out this work. It carries several years of experience in vaccine development projects at MIGAL.migvax.com
Qiryat Shemona, IsraelInaccurate data? Flag it here.
Open jobs at MigVax